Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multi-Centre Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting

NCT02413008 is registered in ClinicalTrials.gov with ITF Research Pharma, S.L.U. as lead sponsor.

NCT NCT02413008
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02413008 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multi-Centre Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting
Lead sponsor
ITF Research Pharma, S.L.U.
Phase
Phase 2
Overall status
Completed
Start date
October 16, 2015
Completion date
February 10, 2017
Enrollment
61 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

vaginal atrophy